- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT03800082
Development and Usability Testing of a Progressive WebApp for Women With Heart Disease (at heart)
Studie Overzicht
Toestand
Conditie
Interventie / Behandeling
Gedetailleerde beschrijving
Phase 3 (Study 3): Pilot Randomized Controlled Trial of the at heart (formerly called HEARTPA♀N) Intervention.
The at heart intervention is the first of its kind; there are no previous trials of the efficacy of such an intervention to decrease pain and improve HRQoL in women with heart disease. The investigators will undertake a process and preliminary effect evaluation of the intervention for women with heart disease, as guided by the MRC framework. The primary objective is to determine the feasibility of implementing an RCT of the intervention. A process evaluation will be conducted to examine: 1) the feasibility of randomization, recruitment and retention, 2) acceptability and barriers to implementing the intervention (including the symptom triage algorithms), and 3) the extent of engagement with the intervention. The investigators will also undertake a preliminary efficacy evaluation of the primary outcomes. Based on the investigator's theorized mechanism of change, they hypothesize that the intervention will reduce pain and improve HRQoL (primary outcomes). The investigators will assess the variability and sensitivity to change for both outcomes. Prior to conducting a full scale RCT of a complex intervention, such as at heart, the MRC recommends that a pilot trial be performed. Results from this pilot trial will inform the success of a future RCT in three ways: 1) help determine sample size calculation for the full-scale trial, 2) test procedures (recruitment, randomization, follow-up), which will make up the design of the full-scale trial, and 3) test feasibility of implementing the intervention, particularly by estimating rates of recruitment and retention. Triage algorithms and self-management interventions will be developed using a strong theoretical framework, informed by needs assessments and a comprehensive integrated mixed methods systematic review, with preliminary acceptability and usability testing by end-users. The investigators anticipate minimal risk to safety but will track adverse events using the Adverse Event Form. Moreover, latest WebApp technologies have been integrated through the use of a Chatbot named 'Holly'.
Studietype
Inschrijving (Verwacht)
Fase
- Niet toepasbaar
Contacten en locaties
Studiecontact
- Naam: Monica Parry, PhD
- Telefoonnummer: 416.946-3561
- E-mail: monica.parry@utoronto.ca
Studie Contact Back-up
- Naam: Myra Leyden, MA
- Telefoonnummer: 416.978.1327
- E-mail: myra.leyden@utoronto.ca
Studie Locaties
-
-
Ontario
-
Toronto, Ontario, Canada, M5T 1P8
- Werving
- Monica Parry
-
Contact:
- Monica Parry, PhD
- Telefoonnummer: 416.946.3561
- E-mail: monica.parry@utoronto.ca
-
Contact:
- Arland O'Hara, BA
- E-mail: arland.ohara@utoronto.ca
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Inclusion Criteria:
- women greater than 18 years of age with obstructive and non-obstructive CAD pain, post PCI/cardiac surgery pain lasting greater than 3 months
- women will be required to speak and read English
Exclusion Criteria:
- severe cognitive impairment assessed using the Six-Item Screener
- major co-morbid medical or psychiatric illness that could preclude their ability to participate
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Ondersteunende zorg
- Toewijzing: Gerandomiseerd
- Interventioneel model: Parallelle opdracht
- Masker: Enkel
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
|---|---|
|
Geen tussenkomst: Control
Participants allocated to the control group will receive the usual care and supports provided to women with cardiac pain, including usual clinic appointments and follow-up.
|
|
|
Experimenteel: Treatment
Participants allocated to the treatment group will also learn how to use the progressive WebApp intervention.
The intervention will be delivered on restricted password-protected applications that will permit tracking of adherence (number of logins to app and website using Google Analytics).
Participants will be encouraged to log-in regularly to the progressive WebApp (via automated alerts) over the 3-month period to complete a Heart and/or Wellness Check.
A Chatbot named 'Holly' will assist women with log-in and maintaining health and wellness.
Participants will be directed to the PC for technical problems.
|
An integrated smartphone and web-based intervention (at heart) to provide evidence-informed symptom triage and self-management support to reduce pain and increase health-related quality of life (HRQoL) in women with heart disease.
The intervention for participants randomized to the treatment group will consist of regular use of a progressive WebApp that is managed by a Chatbot named 'Holly', in addition to usual care, for a period of 3 months.
|
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Feasibility (recruitment, retention, engagement)
Tijdsspanne: 3 months
|
A process evaluation will be used to assess the feasibility of the implementation of the intervention.
The PC will track any issues or difficulties encountered during trial implementation, such as problems using the app.
Engagement will be assessed using Google Analytics, which will track patterns of app and website usage.
Engagement with the app diary will be defined as 100% with daily entries for 3 months.
Engagement with goal setting will be defined as 100% when 12 goals are identified over the 3-month period.
Criteria for implementation success: recruitment rates > 70%, retention > 85%, minimal technical difficulties reported by < 10%, engagement > 80%, and minimal missed responses.
Prevalence of refusal, retention, engagement and technical difficulties reported will be calculated with their 95% confidence intervals.
|
3 months
|
|
Feasibility (acceptability, satisfaction)
Tijdsspanne: 3 months
|
The investigators will also assess acceptability and satisfaction in all participants in the intervention group using a modified Acceptability e-Scale (AES).
The modified AES includes 9 items, each with a 5-point Likert response.
Higher scores represent better acceptability/satisfaction.
Responses are summed and averaged.
Criteria for implementation success: AES mean summary score > 4.
|
3 months
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Pain (Brief Pain Inventory)
Tijdsspanne: 3 months
|
A preliminary efficacy evaluation will also be undertaken focusing on the outcomes of pain.
Pain will be measured using the Brief Pain Inventory-Short Form (BPI-SF), which rates pain severity and the degree to which pain interferes with mood, sleep, and other physical activities such as work, social activity and relations with others.
We will investigate the variability and sensitivity to change for pain (T2-T1).
We will calculate the number of participants who report clinically meaningful decreases in pain, which has been defined for the BPI-SF as a two-point difference in worst pain.
Variability will be estimated using the mean/median scores and standard deviation, in each group separately, at pre and post-test.
|
3 months
|
|
Health-related quality of life (HRQOL)
Tijdsspanne: 3 months
|
A preliminary efficacy evaluation will also be undertaken focusing on the outcomes of HRQOL.
HRQOL will be measured using the SF-36v2TM, which contains 36 items and yields a score for each of the 8 domains of health: physical functioning, role limitations due to physical health (role-physical), bodily pain, general health perceptions, vitality, social functioning, role limitations due to emotional problems (role emotional), and mental health.
We will investigate the variability and sensitivity to change for HRQOL (T2-T1).
Sensitivity to change will be assessed by determining the number of participants who had a clinically meaningful increase in HRQOL: ≥ 15 points in physical functioning, general health and mental health; ≥ 16.7 in role emotional functioning; ≥ 18.5 points in role physical functioning and vitality; ≥ 20 points in bodily pain; and ≥ 25 points in social functioning.
|
3 months
|
Medewerkers en onderzoekers
Sponsor
Onderzoekers
- Hoofdonderzoeker: Monica Parry, PhD, University of Toronto
Publicaties en nuttige links
Studie record data
Bestudeer belangrijke data
Studie start (Verwacht)
Primaire voltooiing (Verwacht)
Studie voltooiing (Verwacht)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Trefwoorden
Aanvullende relevante MeSH-voorwaarden
Andere studie-ID-nummers
- 389044
Plan Individuele Deelnemersgegevens (IPD)
Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .